Skip to content
Search

Latest Stories

Top Stories

How Congress can quickly make Ozempic, Wegovy affordable

Wegovy box
Jakub Porzycki/NurPhoto via Getty Images

Pearl, the author of “ ChatGPT, MD,” teaches at both the Stanford University School of Medicine and the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

A whopping one in eight U.S. adults have taken GLP-1 drugs like Wegovy and Ozempic for weight loss and related conditions. Their popularity and efficacy have sparked a prescription-writing frenzy in recent years, leaving both medications on the Food and Drug Administration's drug shortage list since May 2023.


But even when the supply rebounds, access to these drugs will remain out of reach for the majority of Americans. That’s because brand-name versions of the drugs range from $11,000 to $16,000 a year, prices that are unaffordable for most people.

Attempts to control prices through legislation face significant hurdles, both in the divided halls of Congress and in the courts, where determined legal challengers await. Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor and Pensions Committee, hopes that applying pressure at upcoming hearings will force Novo Nordisk, maker of Wegovy and Ozempic, to lower prices voluntarily. History shows that pharmaceutical companies rarely bend on prices, even in the face of public scrutiny.

Fortunately, Congress can implement a straightforward solution to make these drugs affordable, thereby improving the nation’s financial and physical health. Before explaining that strategy, here’s why our nation needs effective, affordable and available weight-loss medication.

Framing the obesity epidemic

Around 42 percent of American adults are obese, putting them at dramatically elevated risk for a host of complications: diabetes, heart disease, kidney failure, leg amputation, cancer and severe musculoskeletal problems. The economic impact of obesity is staggering, with related health care costs estimated to be $260 billion annually.

For decades, health experts have pleaded with Americans to exercise more, eat better, and make lifestyle improvements while urging lawmakers to regulate food and address the “social determinants of health” that lead to excess weight gain. Currently, billions of taxpayer dollars are spent on government-run nutrition and exercise campaigns — on top of the $190 billion Americans spend on weight loss products, programs and supplements.

Despite these extensive efforts and expenditures, obesity rates continue to climb, as do the associated consequences, contributing to as many as 500,000 preventable deaths every year.

The outsized promise of GLP-1 drugs

Studies show that all GLP-1 drugs lead to major weight loss, averaging 15 percent of a user’s body mass. And when obese individuals combine regular exercise with semaglutide, the active ingredient in Wegovy, they shed an average of 34 pounds.

Beyond weight loss, GLP-1 medications have been shown to reduce the incidence of diabetes and cardiovascular events, prevent kidney failure and potentially improve cognitive function in patients with Alzheimer’s.

Despite all the known and potential benefits, the high price of weight-loss medications forces insurers and employer health plans to limit coverage, leaving many patients without access to these beneficial solutions.

The current financial burden

The cost of providing 100 percent of obese Americans with GLP-1 medications would surpass $1 trillion a year, even with drug rebates. For perspective, that’s more than twice what Americans spend on all prescription drugs annually. Moreover, that figure dwarfs the $260 billion in projected savings if obesity were eradicated.

And because patients who stop taking the medication regain an average of two-thirds of the weight they’ve lost, that trillion-dollar annual cost would persist indefinitely. From the vantage of the U.S. health care system, this ongoing expense (an estimated 25 percent annual bump in total health care spending) would strain funding for other vital components of care, including hospitals and clinicians. It would also drive insurance premiums and out-of-pocket costs through the roof.

A recent report from Sanders’ office highlighted the stark disparity in global pricing for GLP-1 medications: Americans pay over $1,300 for a 28-day supply of Wegovy while patients pay far less in countries like Denmark ($186), Germany ($137) and the United Kingdom ($92).

This is because nearly all national governments, except for the United States, negotiate the price of prescription medications, rather than allowing drug companies to charge whatever they deem best for their shareholders.

The hidden truth

Contrary to what people might assume, these drugs are not expensive to make. A team of Yale and Harvard scientists determined that semaglutide can be manufactured for less than $5 per month.

In May 2024, telehealth company Hims & Hers began selling a compounded (pharmacist created) version of the GLP-1 drug semaglutide for $199 per month, about 85 percent less than the brand names Wegovy and Ozempic. This reflects a profitable, but more appropriate, price point.

Hims & Hers can sell its version of these patented weight-loss drugs because Congress has authorized the compounding and sale of a patented drug when there is an FDA-determined drug shortage. However, once the GLP-1 shortage is resolved, companies like Hims & Hers will be required to cease production. This will compromise the health of current users and price out many more Americans still struggling to lose weight.

A creative solution for the FDA and Congress

Congress can make these lifesaving weight loss medications affordable for all eligible Americans by expanding the FDA’s definition of “drug shortage.” Whereas “shortage” currently refers only to inadequate supply, a more modern definition would include medications that are unaffordable and therefore inaccessible to millions of people.

By amending the Food, Drug, and Cosmetic Act, this expanded definition would allow compounded versions to remain available at a reasonable price, even when weight-loss drug manufacturers increase production.

The reason drug manufacturers price GLP-1s at $10,000 to $16,000 a year has little to do with research and development, overhead, or manufacturing costs. The reason is simple: greed.

Such pricing strategies might be tolerable in other industries, but when the health of tens of millions of Americans is at risk, Congress has an obligation to act. Expanding the definition of “shortage” would break the monopolistic hold of current manufacturers, improve public health, save lives and incentivize GLP-1 manufacturers to reduce prices. The time for legislative action is now.

Read More

Public Health: Ban First, Study Later? The Growing Assault on Fluoridated Water

Someone getting tap water.

Getty Images, urbazon

Public Health: Ban First, Study Later? The Growing Assault on Fluoridated Water

On May 15, Florida became the second state in the nation to ban fluoride from public drinking water. The bill, signed by Governor Ron DeSantis, is set to go into effect on July 1. Utah’s Governor Spencer Cox enacted a similar ban that went into effect this May. Five other states—Kentucky, Louisiana, Massachusetts, Nebraska, and South Carolina—have introduced bills that aim to ban fluoride in public drinking water.

Fluoride is a mineral that, in small quantities, has proven to be effective against tooth decay, caused by bacteria that form in the mouth when we eat or drink. The American Academy of Pediatrics states on its website that studies have shown water fluoridation, an intentional treatment process of public drinking water, reduces tooth decay by about 25% in children and adults alike.

Keep ReadingShow less
The U.S. Is Rushing To Make AI Deals With Gulf Countries, But Who Will Help Keep Children Safe?

A child's hand holding an adult's hand.

Getty Images, LaylaBird

The U.S. Is Rushing To Make AI Deals With Gulf Countries, But Who Will Help Keep Children Safe?

As the United States deepens its investments in artificial intelligence (AI) partnerships abroad, it is moving fast — signing deals, building labs, and exporting tools. Recently, President Donald Trump announced sweeping AI collaborations with Gulf countries like Saudi Arabia and the United Arab Emirates. These agreements, worth billions, are being hailed as historic moments for digital diplomacy and technological leadership.

But amid the headlines and handshakes, I keep asking the same question: where is child protection in all of this?

Keep ReadingShow less
Illinois Residents Grapple With Urban Flooding

Rear view of a person standing in the street flooded with water

Getty Images//Stock Photo

Illinois Residents Grapple With Urban Flooding

Following months of research, canvassing, and listening to community needs, journalists, including Britton Struthers-Lugo, produced solutions-based stories about the challenges faced by the Berwyn, Illinois, community.

In Part 1, Struthers-Lugo examines the issue of urban flooding, a growing concern for residents and infrastructure in Berwyn.

Keep ReadingShow less
Proposed Proof-of-Citizenship Bill Could Impact All Registered Voters in Texas

Opponents of a proof-of-citizenship bill before Texas lawmakers say many women in rural areas, who could get targeted by the bill, do not have a birth certificate matching their current last name.

Golib Tolibov/Adobe Stock AI

Proposed Proof-of-Citizenship Bill Could Impact All Registered Voters in Texas

Voting rights advocates in Texas are speaking out against a proof-of-citizenship bill before lawmakers.

Senate Bill 16 would require new registrants and some existing registered voters to prove they are U.S. citizens.

Amber Mills, issue advocacy director for the Move Texas Civic Fund, said the requirement would be in addition to what the state already does to check someone's eligibility.

"When you're completing a voter form, you do also have to submit either your driver's license number or your Social Security number," Mills pointed out. "That's really important because that is how the state verifies who you are, and that's a key indicator that they use to protect their databases on the back end."

Even if you were born in the U.S., the bill could require you to show proof of citizenship with a passport or birth certificate matching your current name. According to the Secure Democracy Foundation, more than 38% percent of rural and small-town Texans do not have a passport.

Anyone who cannot prove citizenship would be placed on a separate voter roll and could only cast ballots in the U.S. House and Senate races.

Emily French, policy director for the advocacy group Common Cause Texas, said the additional barriers could prevent many residents from casting their votes in local, state and presidential races.

"All the DPS systems, all the immigration systems which say that they are citizens, but there can still be mistakes that mark them as noncitizens and could throw them off the voter rolls until they come in with these documents that they don't have," French explained.

The bill directs the Texas Secretary of State's Office to check all registered voters' status by the end of the year and send the names of registered voters who have not proven their citizenship before September 2025 to county elections offices.

Mills noted if you are flagged, there is no online system to comply with the request and all paperwork must be submitted in person.

"We are not disputing the goal of having only eligible citizens on the voter rolls, but we know that Texas already has strong systems in place," Mills emphasized. "It's ultimately the state's responsibility, the county's responsibility to do these voter roll checks, but what SB 16 would do is not change any of that, not improve any of that. It would just add an additional burden."

Proposed Proof-of-Citizenship Bill Could Impact All Registered Voters in Texas was originally published by the Public News Service and is republished with permission.

Keep ReadingShow less